Comparative Pharmacology
Head-to-head clinical analysis: CAROSPIR versus TRIAMTERENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAROSPIR versus TRIAMTERENE.
CAROSPIR vs TRIAMTERENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldosterone antagonist; competitively inhibits aldosterone binding to mineralocorticoid receptors in renal distal tubules, increasing sodium and water excretion while retaining potassium. Also has weak antagonistic activity at androgen receptors.
Triamterene is a potassium-sparing diuretic that inhibits epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, reducing sodium reabsorption and potassium excretion.
Spironolactone 25-100 mg orally once daily. Initial: 25 mg once daily; titrate at 4-week intervals based on response and potassium levels. Maximum: 100 mg/day.
100-300 mg orally once daily; maximum 300 mg/day.
None Documented
None Documented
Clinical Note
moderateTriamterene + Digoxin
"The therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Acetyldigitoxin
Spironolactone has a short half-life of 1.3-2.0 hours, but its active metabolite canrenone has a prolonged half-life of 13-24 hours (mean 18 hours), leading to a sustained pharmacodynamic effect requiring 2-3 days to reach steady state.
Terminal elimination half-life is approximately 1.5 to 2 hours. However, in patients with hepatic cirrhosis, half-life may be prolonged up to 4 hours; in renal impairment, half-life can extend significantly (up to 10 hours) due to reduced renal clearance.
Approximately 50-60% of the dose is excreted in urine as active metabolites (primarily canrenone) and unchanged drug, with about 10-20% as unchanged spironolactone. Fecal excretion accounts for 20-30%, mainly as metabolites.
Approximately 50% of an oral dose is excreted unchanged in urine; about 20% is excreted as metabolites (mainly hydroxytriamterene sulfate conjugate) in urine; biliary/fecal excretion accounts for less than 10%.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene."